Recipharm AB has reached an agreement to acquire the remaining 26% of shares of Nitin Lifesciences Ltd. for a total consideration of approximately $42.7 million.   Thomas Eldered, chief executive officer of Recipharm said, “I have been particularly pleased with the way the performance in Nitin Lifesciences has developed since it became part of the Recipharm Group. Both sales and margins have grown in the business despite the recent macro-economic volatility in India and we foresee this favorab...